<DOC>
	<DOC>NCT00441246</DOC>
	<brief_summary>The objective of the study is to evaluate the safety and efficacy of Mucinex D tablets in providing symptom relief when administered as an adjunct to antibiotic therapy in patients with acute respiratory infection.</brief_summary>
	<brief_title>Phase 4 Study - Mucinex D as Adjunct Therapy</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<criteria>Ages Eligible for Study: 18 to 75 years, Genders Eligible for Study: Both Adult patients presenting at the physician's office with symptoms diagnostic for acute respiratory infection, such as bronchitis or rhinosinusitis; with a clinical diagnosis of acute respiratory infection, meeting the physician's usual diagnostic criteria in practice for prescription of oral antibiotics. The investigator will evaluate patients on a total of seven criteria for inclusion. Have chronic, recurring respiratory signs and symptoms, such as allergic rhinitis or chronic bronchitis, which, in the investigator's opinion, would confound interpretation of symptoms ratings for the acute respiratory infection; The Investigator will evaluate patients on twelve additional criteria for exclusion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Acute Respiratory Infection</keyword>
	<keyword>Bronchitis</keyword>
	<keyword>Rhinosinusitis</keyword>
</DOC>